Malignant Neoplasm Therapeutics Market Overview
Malignant Neoplasm Therapeutics Market Size is estimated to reach $3.1 billion by 2027 and is poised to grow at a CAGR of 9.3% over the forecast period of 2022-2027. A malignant neoplasm is a disorder that occurs when a large number of cells grow abnormally and spread to surrounding or other bodily parts. Mesothelioma, a malignant neoplasm of the mesothelium, melanoma, a malignant tumor arising from melanocytes, seminoma, a malignant neoplasm of the testicular epithelium and lymphoma are the few main forms of malignant neoplasm. Of the above various types of malignant neoplasm cancer, melanoma is one of the most serious types of cancer. According to a research article published by JAMA Network in March 2022, in 2020 an estimated total of 3,25,000 new melanoma cases (1,74,000 males, 1,51,000 females) and 57,000 deaths (32,000 males & 25,000 females) caused by melanoma cancer around the world. Owing to such a high prevalence of Malignant Neoplasm cancer the demand for various diagnostics, treatments and therapeutics is increasing rapidly. Such a growing need for various diagnostics, treatment and therapies increase the interest of the key market players in the development of new therapeutics. In October 2021, the Food and Drug Administration approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor). Such new innovative treatment and therapies and their high demand for malignant neoplasm drive the growth of the Malignant Neoplasm Therapeutics Industry over the forecast period 2022-2027.
Malignant Neoplasm Therapeutics Market Report Coverage
The “Malignant Neoplasm Therapeutics Market Forecast (2022-2027)" by Industry ARC, covers an in-depth analysis of the following segments in the Malignant Neoplasm Therapeutics Market.
- Geographically, North America held a dominant market share in the year 2021, owing to the developed healthcare infrastructure in this region and government support for the development and innovation of new therapeutics surging growth of the Malignant Neoplasm Therapeutics Market Size.
- The Malignant Neoplasm Therapeutics Market is predicted to increase owing to the growing prevalence of various types of malignant neoplasm cancer and the growing demand for treatment fueling the growth of the Malignant Neoplasm Therapeutics Market.
- However, the high cost of treatment and low availability of primary care may limit malignant neoplasm industry growth over the forecast period 2022-2027.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Malignant Neoplasm Therapeutics Market Report.
Malignant Neoplasm Therapeutics Market: Market Share (%) by region, 2021
For More Details On this report - Request For Sample
Malignant Neoplasm Therapeutics Market Segment Analysis - by Type
Malignant Neoplasm Therapeutics Market based on type can be further segmented into Carcinomas, Sarcomas, Myelomas, Leukaemia, Lymphomas and Others. The Carcinomas segment held a dominant market share in the year 2021, as this is the most commonly diagnosed cancer accounting for 80% to 90% of all cancer diagnoses. The carcinoma cancer is again segmented into three types, that is adenocarcinoma, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Adenocarcinoma is the most common form of lung cancer. About 40 percent of all lung cancers are adenocarcinomas. Basal cell cancer is the most common form of skin cancer, accounting for nearly 80% of all skin cancers but in most cases, it is non-fatal.
However, Lymphomas are estimated to grow with the fastest CAGR of 10.5% over the forecast period 2022-2027. This is owing to the growing cases of lymphomas in the world. According to the 2020-2021 report presented by the Leukemia & Lymphoma Society, from the total of 1,86,400 cases of leukemia, myeloma and lymphoma in 2021 in the United States, lymphoma accounts for 48% of total cases, that is 90,390. Such growing cases of lymphoma surge demand for various therapeutics and drive the growth of the Malignant Neoplasm Therapeutics Market Share over the forecast period 2022-2027.
Malignant Neoplasm Therapeutics Market Segment Analysis - by Treatment
Malignant Neoplasm Therapeutics Market based on the treatment can be further segmented into Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy and Others. The surgery segment held a dominant market share in the year 2021. This is owing to the growing cases of malignant cancer and the need for the removal of tumors. The various types of techniques such as laser, cryosurgery, hyperthermia and photodynamic therapy are used for the removal of cancerous cells. According to the ‘Breast Cancer Organisation’, in 2022 an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the United States. Such a growing need for surgery for the removal of cancer drive the growth of the Malignant Neoplasm Therapeutics Market Share.
However, Targeted Therapy is estimated to grow with the fastest CAGR of 10.8% over the forecast period 2022-2027. This is owing to the attribute of targeted therapy which acts on specific genes or proteins required for the survival of cancer cells. Targeted therapy is highly effective for the treatment of cancer when compared to chemotherapy. The success rate of targeted therapy is up to 80%, while for chemotherapy it is about 30%. Owing to the high success rate of targeted therapy more people turn towards it which increases the demand for drugs used in this therapy. In August 2022, the U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Such high popularity of targeted therapy and growing innovations drive the growth of the Malignant Neoplasm Therapeutics Market share over the forecast period 2022-2027.
Malignant Neoplasm Therapeutics Market Segment Analysis - by Geography
The Malignant Neoplasm Therapeutics Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America held a dominant market share of 36% in the year 2021. This is owing to the busy and hectic lifestyle of people and the increase in consumption of unhealthy food, alcohol and smoking. According to the American Cancer Society, the estimated number of new cancer cases and deaths in 2022 stands at 1.9 million newly diagnosed cancer cases and 6,09,360 cancer deaths in the United States. According to the National Cancer Institute, approximately 39.5% of men and women will be diagnosed with cancer at some point during their lifetimes. Such a growing prevalence of cancer and the availability of the best healthcare facilities drive the growth of the Malignant Neoplasm Therapeutics Market Size in this region.
Furthermore, Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027. This is owing to the increasing share of the geriatric population in the total population and the high risk of cancer at age 65 and above. According to the research paper published by SAGE Journal in June 2022, the cancer incidence in Asia was 169.1 per 1 00 000, accounting for 49.3% of the global cancer incidence in the year 2020. And its mortality was 101.6 per 1 00 000 (58.3% of the global cancer death) with lung (19.2%), liver (10.5%) and stomach (9.9%) cancers being the most common causes of cancer death. Such a high rate of cancer and growing mortality rate fuel the growth of the Malignant Neoplasm Therapeutics Market size over the forecast period 2022-2027.
Malignant Neoplasm Therapeutics Market Drivers
Growing Geriatric Population Drive Market Growth.
The incidence of cancer cases is high in the elderly age. Incidence rates for cancer rise consistently with age, from less than 25 cases per 100,000 in the under-20 age group to roughly 350 per 100,000 in the 45–49 age group to more than 1,000 per 100,000 in the 60–plus age group as per the study conducted by National Cancer Institute in 2021. Also, as per the Union for International Cancer Control (UICC), there are currently more than 703 million persons over 65 in the world, that is 9.1% of the total population and by 2050, it is predicted that this percentage will increase to 15.9% (1.5 billion people). Such a high incidence of cancer in elderly people and the growing geriatric population fuels the growth of the Malignant Neoplasm Therapeutics Industry over the forecast period 2022-2027.
Growing Research for Development of New Drugs and Therapies Drive Malignant Neoplasm Therapeutics Market Growth.
To treat different types of cancer different medications and therapies are practiced owing to the complex nature of cancer. From the variety of therapy available for the treatment of cancer such as Hormone therapy, immunotherapy, photodynamic therapy, radiation therapy, chemotherapy, stem cell transplants, targeted therapy and others; chemotherapy and targeted therapy are mostly used nowadays. For instance, in May 2022, The FDA approved fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti-HER2-based regimen either in the metastatic situation or in the neoadjuvant or adjuvant setting and who have experienced disease recurrence during or within 6 months of finishing therapy. Also, in the year 2021, FDA approved 46 new drugs for cancer treatment, such an increasing number of drugs in the market for the treatment of cancer drive the growth of the Malignant Neoplasm Therapeutics Industry over the forecast period 2022-2027.
Malignant Neoplasm Therapeutics Market Challenge
High Cost of Treatment is Hampering Market Growth
The cost for treatment of cancer varies and depends on the type of cancer, its stage and the treatment provided to the patient. According to a report published by the American Cancer Society 2020, In 2019 cancer patients in the U.S. paid $5.6 billion out of pocket for cancer treatments and the National Cancer Cost is projected to increase from $200.7 billion in 2020 to $245.6 billion by 2030. With treatment for cancer the cost for transportation, lodging, caretaking cost, secondary effects cost and loss of income increase the actual cost of cancer treatment. Such a high cost of cancer treatment may limit the growth of the Malignant Neoplasm Therapeutics Industry growth over the forecast period 2022-2027.
Malignant Neoplasm Therapeutics Market Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Malignant Neoplasm Therapeutics Market. The top 10 companies in the Malignant Neoplasm Therapeutics Market are:
- AbbVie Inc.
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Johnson & Johnson
- Merck KGaA
- Celgene Corporation
- AstellasPharma Inc.
- Novartis AG
- Eli Lilly and Company
- In July 2022, Astellas Pharma Inc. announced plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. Astellas invests approximately $70 million to create the new state-of-the-art facility, which will provide lab and co-working spaces to accommodate future growth as it advances a range of innovative cell and gene therapies for patients.
- In June 2022, Bristol Myers Squibb and Turning Point Therapeutics, Inc. announced a definitive merger agreement for the acquisition of Turning Point Therapeutics. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis.
- In May 2022, AbbiVie and Gedeon Richter Plc. announced a new co-development and license agreement to research, develop and commercialize novel dopamine receptor modulators for the potential treatment of neuropsychiatric diseases. The collaboration is based on the results of preclinical research carried out by Richter and includes several new chemical entities selected for development.
Report Code: HCR 0078
Report Code: HCR 0195
Report Code: HCR 0194
For more Lifesciences and Healthcare Market reports, please click here